雷帕鸣治疗效果怎么样？

(sirolimus) is a new type of immunosuppressant. Studies have shown that its immunosuppressive strength is superior to that of cyclosporine, which is currently commonly used. After entering the body, the drug binds to FK-binding protein-12 (FKBP-12), inhibits the specific regulatory protein (mTOR), and then blocks the binding of interleukin-2 (IL-2) to its receptor, inhibiting T lymphocytes from entering the S phase from G1 phase, so that Tc and Td cells cannot become sensitized T lymphocytes with immune response. So, how effective is India Biocon’s rapamycin treatment?

In order to verify the effectiveness and safety of sirolimus (i.e. rapamin) in conversion therapy for kidney transplant recipients, a domestic experiment conducted a conversion therapy based on sirolimus on 50 recipients who were mainly taking oral calcineurin inhibitors after allogeneic kidney transplantation. Among them, there were 29 males and 21 females, aged (40±13) years old; 7 cases were suffering from calcineurin inhibitor hepatotoxicity, 8 cases were post-transplantation diabetes, 27 cases were chronic allograft nephropathy, and 8 cases were complicated by tumors after transplantation.

The treatment plan for all patients adopts a rapid conversion method, with a single first loading dose of 6 mg, followed by a maintenance dose of 2 mg/d. The dose will be adjusted based on the plasma concentration of sirolimus to maintain the trough plasma concentration at 6 to 10 μg/L. Dynamically observe the blood creatinine level and the incidence of acute rejection after sirolimus conversion, and monitor blood routine, blood sugar, blood lipids, liver function and other indicators, and observe the clinical effects, safety and adverse reactions within 6 months after conversion.

The final study results showed that the incidence of acute rejection within 6 months after rapamycin conversion was 10.1%; recipients who underwent drug conversion due to chronic transplant kidney disease had significantly improved renal function after conversion; other original liver damage and hyperglycemia were mostly improved after conversion; 8 tumor recipients had stable conditions without recurrence within 6 months after conversion, and adverse reactions mainly included hyperlipidemia and proteinuria. Biocon is one of the three largest biotechnology companies in India. The therapeutic effects it produces are equivalent to those of the original drugs, and patients can use them with confidence.

Recommended hot articles: /newsDetail/92415.html